- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01283581
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
September 25, 2019 updated by: Melinta Therapeutics, Inc.
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
The purpose of this study is to compare clinical response to the measurement techniques of several objective measures of clinical efficacy for use in future ABSSSI (Acute Bacterial Skin and Skin Structure Infection) clinical trials
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
256
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36617
- University of South Alabama Medical Center
-
Montgomery, Alabama, United States, 36106
- Drug Research and Analysis Corp
-
-
California
-
Buena Park, California, United States, 90620
- Southbay Pharma Research
-
Chula Vista, California, United States, 91911
- eStudySite
-
La Mesa, California, United States, 91942
- eStudySite
-
Los Angeles, California, United States, 90015
- HealthCare Partners Medical Group
-
Oceanside, California, United States, 92056
- eStudySite
-
Pasadena, California, United States, 91105
- HealthCare Partners Medical Group
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Christiana Care Health Services
-
-
Florida
-
Edgewater, Florida, United States, 32132
- Riverside Clinical Research
-
Jacksonville, Florida, United States, 32207
- River City Clinical Research
-
Kissimmee, Florida, United States, 34741
- Central Florida Internists
-
Orlando, Florida, United States, 32811
- Central Florida Internists Medical
-
Saint Cloud, Florida, United States, 34769
- Central Florida Internists
-
Temple Terrace, Florida, United States, 33617
- Ronald Barbour, MD
-
-
Georgia
-
Columbus, Georgia, United States, 31904
- Southeast Regional Research Group
-
Decatur, Georgia, United States, 30030
- Atlanta Institute For Medical Research, Inc
-
Savannah, Georgia, United States, 31406
- Southeast Regional Research Group
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Kentucky
-
Paducah, Kentucky, United States, 42003
- Four Rivers Clinical Research, Inc
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70810
- Medical Development Centers, LLC
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- University of Missouri Health Care
-
-
Montana
-
Butte, Montana, United States, 59701
- Mercury Street Medical Group, PLLC
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109
- eStudySite
-
-
New Jersey
-
Somers Point, New Jersey, United States, 08244
- South Jersey Infectious Disease
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43215
- Remington-Davis, Inc.
-
Lima, Ohio, United States, 45801
- Ravi Kamepalli, MD
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57702
- Health Concepts
-
-
Texas
-
Houston, Texas, United States, 77002
- Jennifer Johnson-Caldwell, MD
-
Houston, Texas, United States, 77005
- Alan Nolasco, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult (≥ 18 years of age) men or women
- Sexually active women and men with partners of childbearing potential must agree to use an acceptable form of contraception as determined by the investigator during participation in the study and for 30 days after the final dose of study drug
- Female partners of male subjects should also use an additional reliable method of contraception during study and for 30 days after the final dose of study drug
- Subjects must have a diagnosis of ABSSSI - one or more of the following 4 infection types: cellulitis/erysipelas, wound infection, major cutaneous abscess, or burn infection
- Subjects must have lymph node enlargement due to the present infection or at least one of the following symptoms of systemic infection: fever ≥ 38°C, lymphangitis, WBC (white blood cell) count ≥ 15,000 cells/μL, elevated C-reactive protein (> 5.0mg/L)
- In the opinion of the investigator, the subject must require and be a suitable candidate for IV antibiotic therapy
Exclusion Criteria:
- A medical history of significant hypersensitivity or allergic reaction to quinolones, linezolid, vancomycin, or vancomycin derivatives
- Women who are pregnant or lactating
- Any chronic or underlying skin condition at the site of infection that may complicate the assessment of response
- Subjects with any of the following: infection involving prosthetic materials or foreign bodies, infection associated with a human or animal bite, osteomyelitis, decubitus ulcer, diabetic foot ulcer, septic arthritis, mediastinitis, necrotizing fasciitis, anaerobic cellulitis, or synergistic necrotizing cellulitis, myositis, tendinitis, endocarditis, toxic shock syndrome, gangrene, burns covering ≥ 10% of body surface area, severely impaired arterial blood supply, current evidence of deep vein thrombosis or superficial thrombophlebitis
- Minor abscesses, unless present with one of the ABSSSI types
- Any infection expected to require other antimicrobial agents in addition to study drug
- Receipt of > 24 hours of systemic antibiotic therapy in the 14 days before enrollment unless one of the following is documented: the subject received a single dose of a short-acting antibacterial drug 3 or more days before clinical trial enrollment for surgical prophylaxis or recently completed treatment with an antibacterial drug for an infection other than ABSSSI and the drug does not have antibacterial activity against bacterial pathogens that cause ABSSSI
- Receipt of more than 1 dose of a potentially effective antibacterial agent for treatment of the ABSSSI under study prior to enrollment
- Receipt of chronic anti-inflammatory therapy for longer than 14 days before enrollment
- Severely compromised immune systems
- Subjects taking any medicinal product which inhibits monoamine oxidases A or B or within 2 weeks of Screening
- Hypertension as defined by a systolic blood pressure of ≥ 180 mmHg or a diastolic blood pressure of ≥110 mmHg with confirmed re-check within 20 minutes of initial reading
- Subjects with pheochromocytoma, thyrotoxicosis and/or subjects taking any of the following types of medications: sympathomimetic agents, vasopressive agents, dopaminergic agents, or other agents with the potential for serotonergic interactions
- Subjects with carcinoid syndrome and/or subjects taking any of the following medications: serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 (serotonin receptor) receptor agonists, meperidine, or buspirone
- Known history of liver disease
- History of severe renal impairment
- Life expectancy of < 3 months
- Any underlying disease that, in the opinion of the investigator, could interfere with the subject's ability to participate in the study
- Subjects previously randomized in this study or in who have received a dose of an investigational drug within 30 days of randomization
- Subjects > 140 kg in body weight
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Delafloxacin
300 mg IV (intravenous) every 12 hours for 5-14 days
|
300mg IV every 12 hours for 5-14 days
Other Names:
|
Active Comparator: Vancomycin
15 mg/kg, up to 1250 mg, IV every 12 hours for 5-14 dyas
|
15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
Other Names:
|
Active Comparator: Linezolid
600 mg IV every 12 hours for 5-14 days
|
600mg IV every 12 hours for 5-14 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigator's Assessment of Clinical Response in the ITT (Intent-to-treat) Population at Follow-up
Time Frame: Follow-up (Day 14 ± 1)
|
The primary efficacy endpoint was the success rate, defined as (cure)/(cure + failure), and expressed as a percentage.
Cure was defined as the complete resolution of all baseline signs and symptoms of ABSSSI and follow-up and late follow-up.
If erythema was the only sign of infection present at follow-up and it was then absent at late follow-up, the case was classified as a Cure.
|
Follow-up (Day 14 ± 1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Erythema Clinical Success
Time Frame: 48 - 72 hours
|
The number of ITT subjects who had cessation of erythema within 48-72 hours, based on digital measurements, as well as resolution/absence of fever.
Cessation was defined as a percentage change from baseline in total area of erythema/induration that is less than or equal to 0%.
|
48 - 72 hours
|
Pharmacokinetic (PK) Parameter, Area Under Curve, (AUCinf, ug*h/mL), in Subjects Administered Delafloxacin, Vancomycin, and Linezolid
Time Frame: Through Day 3 (± 1 day)
|
Blood samples for pharmacokinetic analyses were drawn from all subjects on Day 3 (± 1 day) of treatment within 2 hours before the first study drug infusion and at 1, 2, 3, 5, and 12 hours (ie, immediately before the second dose) after the start of the first study drug infusion.
An analytical, validated method was used to analyze samples and determine human plasma concentrations.
The primary pharmacokinetic parameter calculated was area under the plasma concentration - time curve from time 0 extrapolated to infinity (AUCinf, ug*h/mL).
|
Through Day 3 (± 1 day)
|
The Levels of Inflammation Were Examined by Measuring a Surrogate, C-Reactive Protein (CRP)
Time Frame: Baseline, Days 1, 5, Follow-up (FU), and late Follow-up (LFU)
|
CRP Levels (g/m3) were analyzed from blood samples collected from subjects at Baseline and various time points throughout the study.
Change in baseline values were analyzed using an analysis of covariance (ANCOVA) model with treatment, infection category, and prior antimicrobial therapy as fixed effects and the baseline measure as the covariate.
|
Baseline, Days 1, 5, Follow-up (FU), and late Follow-up (LFU)
|
Microbiological Response Rate in All Subjects (Microbiological Evaluable Population)
Time Frame: Follow-up (Day 14 ± 1)
|
Based on the results of the baseline and follow up cultures and susceptibility testing, together with the clinical response assigned by the investigator, the sponsor determined a microbiological response for subjects in the ME population.
|
Follow-up (Day 14 ± 1)
|
Microbiological Response Rate in Subjects With MRSA (Methicillin Resistant Staphylococcus Aureus) in Microbiological Evaluable (ME) Population
Time Frame: Follow-up (Day 14 ± 1)
|
Based on the results of the baseline and follow up cultures and susceptibility testing, together with the clinical response assigned by the investigator, the sponsor determined a microbiological response for subjects in the ME population.
|
Follow-up (Day 14 ± 1)
|
Clinical Response in Subjects With Infections Caused by MRSA - Microbiological ITT (MITT) Population
Time Frame: Follow-up (Day 14 ± 1)
|
The success rate, defined as (cure)/(cure + failure), and expressed as a percentage.
Cure was defined as the complete resolution of all baseline signs and symptoms of ABSSSI and follow-up and late follow-up.
If erythema was the only sign of infection present at follow-up and it was then absent at late follow-up, the case was classified as a Cure.
|
Follow-up (Day 14 ± 1)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Scott Hopkins, MD
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Results of a Phase 2 Study of Delafloxacin (DLX) Compared to Vancomycin (VAN) and Linezolid (LNZ) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) J. Longcor 1 , S. Hopkins 1 , L. Lawrence 1 , S. Green 2 , P. Mehra 2 , P. Manos 2 , W. Sears 2 , W. O'Riordan 2 1 Rib - X Pharmaceuticals, Inc., New Haven, CT; 2 eStudySite, San Diego, CA 52nd ICAAC, San Francisco, CA 2012
- Characterization and In Vitro Activity of Delafloxacin (DLX) Against Isolates from a Phase 2 Study of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) L. Lawrence 1 , S. Hopkins 1 , D. Sahm 2 , Jennifer Deane 2 , E. Burak 1 , J. Longcor 1 1 Rib - X Pharmaceuticals, Inc., New Haven, CT; 2 Eurofins Medinet, Chantilly, VA 52nd ICAAC, San Franciso, 2012
- Pharmacokinetics (PK) of Delafloxacin (DLX), Vancomycin (VAN), and Linezolid (LNZ) in a Phase 2 Exploratory Study in Subjects with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) R. Hoover 1 , L. Lawrence 1 , J. Longcor 1 , J. Greenfield 2 1 Rib - X Pharmaceuticals, New Haven, CT; 2 PharmaNet/i3, The Woodlands, TX 52nd ICAAC, San Francisco, CA, 2012
- Kingsley J, Mehra P, Lawrence LE, Henry E, Duffy E, Cammarata SK, Pullman J. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016 Mar;71(3):821-9. doi: 10.1093/jac/dkv411. Epub 2015 Dec 17.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (Actual)
November 1, 2011
Study Completion (Actual)
November 1, 2011
Study Registration Dates
First Submitted
January 24, 2011
First Submitted That Met QC Criteria
January 25, 2011
First Posted (Estimate)
January 26, 2011
Study Record Updates
Last Update Posted (Actual)
October 16, 2019
Last Update Submitted That Met QC Criteria
September 25, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RX-3341-202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin and Subcutaneous Tissue Bacterial Infections
-
Trius Therapeutics LLCCompletedSkin and Subcutaneous Tissue Bacterial InfectionsUnited States, Argentina, Australia, Brazil, Germany, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain
-
Melinta Therapeutics, Inc.CompletedSkin and Subcutaneous Tissue Bacterial InfectionsUnited States, Croatia, Israel, Latvia, Russian Federation, Spain, Ukraine
-
Melinta Therapeutics, Inc.CompletedSkin and Subcutaneous Tissue Bacterial Infections | Skin Structures and Soft Tissue InfectionsUnited States, Argentina, Brazil, Bulgaria, Chile, Estonia, Georgia, Hungary, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Peru, Romania, Slovakia, Taiwan
-
Trius Therapeutics LLCCompletedSkin and Subcutaneous Tissue Bacterial InfectionsUnited States, Argentina, Brazil, Canada, Czechia, Germany, Hungary, Latvia, Peru, Slovakia, Ukraine
-
TenNor Therapeutics LimitedCompletedGram-Positive Bacterial Infections | Skin and Subcutaneous Tissue Bacterial InfectionsUnited States
-
Affinium Pharmaceuticals, LtdCompletedCellulitis | Wound Infection | Skin and Subcutaneous Tissue Bacterial Infections | Cutaneous Abscess | Burn InfectionUnited States, Canada
-
Islamic Azad University of MashhadCompletedSkin and Subcutaneous Tissue Fungal InfectionsIran, Islamic Republic of
-
Washington University School of MedicineActive, not recruitingStaphylococcus Aureus | Skin and Subcutaneous Tissue Bacterial Infections | MRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
Connie PriceUnited States Department of Defense; Accelerate Diagnostics, Inc.CompletedInfection | Skin and Subcutaneous Tissue Bacterial Infections | Healthcare-associated Infection | Infection Due to Resistant BacteriaUnited States
-
Denver Health and Hospital AuthorityUnited States Department of Defense; Accelerate Diagnostics, Inc.CompletedSkin and Subcutaneous Tissue Bacterial Infections | Healthcare-associated Infection | INFECTIONS | Infection Due to Resistant BacteriaUnited States
Clinical Trials on Delafloxacin
-
Melinta Therapeutics, Inc.Completed
-
Melinta Therapeutics, Inc.CompletedHepatic ImpairmentUnited States
-
Melinta Therapeutics, Inc.TerminatedGonorrheaUnited States
-
Melinta Therapeutics, Inc.CompletedSkin and Subcutaneous Tissue Bacterial Infections | Skin Structures and Soft Tissue InfectionsUnited States, Argentina, Brazil, Bulgaria, Chile, Estonia, Georgia, Hungary, Korea, Republic of, Latvia, Mexico, Moldova, Republic of, Peru, Romania, Slovakia, Taiwan
-
Melinta Therapeutics, Inc.CompletedSkin and Subcutaneous Tissue Bacterial InfectionsUnited States, Croatia, Israel, Latvia, Russian Federation, Spain, Ukraine
-
Melinta Therapeutics, Inc.CompletedStaphylococcal Skin Infections | Bacterial Skin Diseases | Skin Structure InfectionsUnited States, Puerto Rico
-
Melinta Therapeutics, Inc.CompletedVA Drug InteractionsUnited States
-
Melinta Therapeutics, Inc.CompletedCommunity Acquired Bacterial PneumoniaUnited States, Argentina, Bulgaria, Colombia, Dominican Republic, Georgia, Germany, Hungary, Latvia, Peru, Poland, Romania, Russian Federation, Serbia, Slovenia, South Africa, Spain, Ukraine
-
Menarini GroupTerminated
-
West Virginia UniversityEnrolling by invitationSkin and Soft Tissue Infection | Gastrointestinal Infection | Pulmonary Infection | Bone and Joint Infection | Endovascular Infection | Genitourinary InfectionUnited States